» Articles » PMID: 37739311

Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01

Abstract

Background: Intravenous vancomycin therapy can cause liver injury as well as "drug reaction with eosinophilia and systemic symptoms" (DRESS) syndrome. This study aimed to better define the clinical features and HLA associations of vancomycin-induced liver injury.

Objective: To describe clinical, biochemical, and temporal characteristics of vancomycin-induced liver injury.

Methods: Cases of liver injury with recent exposure to vancomycin who were enrolled in the US Drug-induced Liver Injury Network between 2004 and 2020 were assessed. Sequencing of HLA alleles was performed on stored blood samples.

Results: Among 1697 cases of drug-induced liver injury identified between 2004 and 2021, 9 (0.5%) were attributed to intravenous vancomycin. The 9 cases included 6 men, median age 60 years (range, 23-85 days), and treatment for 26 days (range, 1-34 days). The clinical presentation was DRESS syndrome in 8 patients, of whom 6 received corticosteroids. Liver injury varied from hepatocellular to cholestatic and from mild (n = 5) to fatal (n = 1). In survivors, liver injury and DRESS syndrome ultimately resolved. HLA typing demonstrated the HLA-A∗32:01 allele in 7 vancomycin cases (78%, all with DRESS syndrome), versus 1 of 81 cases (1.2%) exposed but not attributed to vancomycin, and 113 of 1708 cases (6.6%) without vancomycin exposure. The allele frequency in vancomycin cases was 0.44 compared with less than 0.04 in US populations.

Conclusions: Vancomycin-induced liver injury is commonly associated with DRESS syndrome and linked to HLA-A∗32:01. HLA-A∗32:01 testing could be considered early to risk-stratify patients using long-term intravenous vancomycin therapy.

Citing Articles

Vancomycin Drug Reaction with Eosinophilia and Systemic Symptoms: Meta-Analysis and Pharmacovigilance Study.

Aboukaoud M, Adi Y, Abu-Shakra M, Morhi Y, Agbaria R J Clin Med. 2025; 14(3).

PMID: 39941601 PMC: 11818417. DOI: 10.3390/jcm14030930.


Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature.

Singh H, Kunkle B, Troia A, Suvarnakar A, Waterman A, Khin Y Drug Saf. 2025; .

PMID: 39921708 DOI: 10.1007/s40264-025-01514-z.


Risk factors for drug hypersensitivity reactions in children.

Mori F, Saretta F, Riscassi S, Caimmi S, Bottau P, Liotti L Ital J Pediatr. 2024; 50(1):127.

PMID: 39010141 PMC: 11247891. DOI: 10.1186/s13052-024-01694-x.


The clinical application of genetic testing in DILI, are we there yet?.

Krantz M, Marks M, Phillips E Clin Liver Dis (Hoboken). 2024; 23(1):e0218.

PMID: 38872778 PMC: 11168851. DOI: 10.1097/CLD.0000000000000218.

References
1.
Sim D, Yu J, Jeong J, Jung J, Kang H, Kang D . Variation of clinical manifestations according to culprit drugs in DRESS syndrome. Pharmacoepidemiol Drug Saf. 2019; 28(6):840-848. DOI: 10.1002/pds.4774. View

2.
Wolfson A, Zhou L, Li Y, Phadke N, Chow O, Blumenthal K . Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. J Allergy Clin Immunol Pract. 2018; 7(2):633-640. PMC: 6363826. DOI: 10.1016/j.jaip.2018.08.013. View

3.
Wilhelm M, Estes L . Symposium on antimicrobial agents--Part XII. Vancomycin. Mayo Clin Proc. 1999; 74(9):928-35. DOI: 10.4065/74.9.928. View

4.
Chalasani N, Bonkovsky H, Fontana R, Lee W, Stolz A, Talwalkar J . Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015; 148(7):1340-52.e7. PMC: 4446235. DOI: 10.1053/j.gastro.2015.03.006. View

5.
Chen Y, Yang X, Zeckel M, Killian C, Hornbuckle K, Regev A . Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf. 2010; 34(1):73-82. DOI: 10.2165/11539560-000000000-00000. View